Catalyst Wire Dossier Catalyst Wire Dossier

Targeted NY-ESO-1 TCR-engineered autologous T cells

· Fudan University
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Targeted NY-ESO-1 TCR-engineered autologous T cells, covering 2017-02-09 to 2017-02-09. Get the full timeline:

Most recent: Clinical Trial Update: The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors [NA]

See pricing